DIA Biosimilars 2013

GenVec

GenVec board restructures operations, withdraws plan of dissolution

Wednesday, September 4, 2013 12:11 PM

The board of directors of GenVec, a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines, has withdrawn the Plan of Complete Liquidation and Dissolution for the company, previously adopted May 24.

More... »

Cenduit: Now with Patient Reminders

GenVec, Naval Medical Research Center enter $3.5 million contract

Thursday, May 30, 2013 03:19 PM

GenVec, a biopharmaceutical company focused on therapeutics and vaccines, has signed an agreement worth approximately $3.5 million with the Naval Medical Research Center (NMRC) to support malaria vaccine development. 

More... »

CRF Health – eCOA Forum

BioDelivery Sciences appoints Thomas W. D'Alonzo to board of directors

Tuesday, April 30, 2013 08:00 AM

BioDelivery Sciences International, a specialty pharmaceutical company, has appointed Thomas W. D'Alonzo to the company's board of directors.

More... »

GenVec cuts workforce by 30%

Tuesday, September 25, 2012 01:52 PM

GenVec, a biopharmaceutical company based in Gaithersburg, Md., is lowering its operating costs to conserve capital including eliminating 23 positions, or approximately 30% of its workforce.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs